BioSpain 2025 Will Address Advances in Gene Therapies, mRNA Vaccines and Crispr-Cas

The Spanish Association of Biocompanies (AseBio) has presented, together with the Generalitat de Catalunya and the Barcelona City Council, the BioSpain 2025 congress, a reference event in the biotechnology sector at a national level and one of the main ones at a European level.

Rocío Arroyo, president of Asebio, has commented that BioSpain 2025 will have a “top-level scientific program” to address the global challenges of the sector: the decoding of the genome in gene therapies, messenger RNA ( mRNA ) vaccines, the role of Crispr-Cas in gene editing, microbial resistance , or the challenges in the manufacturing and access to new therapies.

“There will also be a debate on emerging tools such as synthetic biology, artificial intelligence or new applications in foodtech and sustainable food, where at Asebio we see a lot of potential for growth,” he said. Other technologies such as microfluidics and multiomic platforms , which open up new possibilities in research, clinical trials and technology transfer, will also have their place in the BioSpain 2025 programme, which will have Switzerland as a guest country.

Biotechnology – A strategic sector

“Biotechnology is a strategic and transformative sector in key sectors beyond health, such as food, energy and sustainability. Thanks to biotechnology, we can face global challenges, as has recently happened with the pandemic,” said the president of Asebio. In a global context where strategic autonomy is increasingly important, she said that biotechnology is key to improving Europe’s competitiveness against other countries such as the United States and China.

In addition, he stressed the importance of BioSpain as a catalyst for investment and innovation in the sector. According to data from AseBio, in 2023 Spain had almost 1,000 companies dedicated to biotechnology and more than 4,400 indirectly related companies. The sector had a turnover of 20 billion euros and generated an added value of 6.8 billion, attracting investments of 228 million.

“Our ambition is to continue internationalizing BioSpain and position it as a bridge between the American, Spanish and European ecosystems, with a geographic focus on Spain. We encourage you all to join us in this new edition so that, once again, BioSpain breaks records and consolidates its position as the great reference event for biotechnology in Europe ,” he said.

For his part, Javier Padilla , Secretary of State for Health, stressed that ” innovation is inherent to the biotechnology field and must be valued as something fundamental for the scientific and health development of the country. Europe has two options: to stay behind or to be a place at the forefront of high-value technologies that serve to improve people’s lives .”

Barcelona, ​​host for the next three editions

The capital of Catalonia will once again host the congress after the success of 2023, which broke attendance records by bringing together more than 2,200 professionals from more than 1,000 companies from more than 34 countries, and which had more than 81 national and international investors. “More and more investors are betting on Spanish biotechnology . BioSpain is a platform to boost startups ,” said the president of Asebio.

During the conference presentation event, it was confirmed that Barcelona will also be the venue for future editions in 2027 and 2029. “This new edition will be decisive in generating business opportunities and facilitating collaboration between all the agents in the sector’s value chain and, therefore, in accelerating the arrival of new technologies to the market and to patients,” said Robert Fabregat, CEO of Biocat.

“The celebration of BioSpain, once again, as the main meeting point for the sector , places us at the epicentre of this field in Europe and demonstrates to the world the talent and experience that this industry brings together, one of those that contributes most to the economy of Catalonia as a whole,” said Joan Romero , executive director of Acció de la Generalitat de Catalunya.

According to data from the annual study carried out by AseBio on the biotechnology sector , in 2023 Catalonia once again led the number of biotech companies , with more than 24% of the total number of companies and exceeding 35% of the total turnover at the state level. The community has the companies with the highest average turnover in a strategic sector for the economy of Spain as a whole, to which it contributes 1.26% of GDP .

BioSpain: bet on green biotechnology

At this edition, BioSpain will give greater prominence to green biotechnology , with an expansion and greater visibility of its specialized track in this area. Startups, companies and experts will showcase advances in regenerative agriculture, emissions reduction and environmental preservation .

During this BioSpain 2025 presentation event, a round table moderated by Ion Arocena , CEO of Asebio, was also held, with the participation of Guillem Laporta , partner at Ysios Capital; Elena Erroba , director of business development, communication and marketing at 3P Biovian; and Lucía Díaz , director of the Drug Discovery department at Nostrum Biodiscovery. In this space, the participants highlighted the importance of Biospain, as well as the good expectations they have regarding the 2023 edition.

__

(Featured image by Logan Armstrong via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us